NuCana plc

General Information

We are a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for cancer patients by applying our ProTide technology to transform some of the most widely prescribed chemotherapy agents, nucleoside analogs, into more effective and safer medicines. While these conventional agents remain part of the standard of care for the treatment of many solid tumors, their efficacy is limited by cancer cell resistance mechanisms and they are often poorly tolerated. Utilizing our proprietary technology, we are developing new medicines, ProTides, designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells.

Employees: 16
Founded: 1997
Contact Information
Address 10 Lochside Place, Edinburgh, EH12 9RG, United Kingdom
Phone Number +44 (0)131 248 3660
Web Address
View Prospectus: NuCana plc
Financial Information
Market Cap $463.2mil
Revenues $0 mil (last 12 months)
Net Income $-9.9 mil (last 12 months)
IPO Profile
Symbol NCNA
Exchange NASDAQ
Shares (millions): 6.7
Price range $15.00 - $15.00
Est. $ Volume $100.0 mil
Manager / Joint Managers Citigroup/ Jefferies/ Cowen
CO-Managers William Blair
Expected To Trade: 9/28/2017
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change